drugset
drugset / Trial / NCT03473457

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia

NCT03473457 ↗

Terminated 2 enrolled Zhujiang Hospital Nanfang Hospital, Southern Medical University · collabSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabThe Third Affiliated Hospital of Southern Medical University · collab
NaSingle-groupOpen-labelTreatment

Summary

Acute myeloid leukemia (AML) is a group of genetically highly heterogeneous malignant disease . The disease is the most common type of adult acute leukemia. Overall survival (OS) was less than 50% in 5 years. Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy is one of revolutionary targeted immunotherapy. The efficacy of CAR-T cells for the treatment of acute B lymphocytic leukemia has been widely recognized, although it start late, several clinical trials have been register in ClinicalTrials.gov.

Timeline

Start
2018-04-01
Primary completion
2020-12-31
Completion
2020-12-31

Outcome

Outcome not reported

Stopped: “The therapeutic effect was not as expected”

Drugs

EvaluationDrugModalityDoseRoute
Subject CD117-CART Unknown 1e+06 cells/kg —
Subject CD117-CART Unknown 1e+07 cells/kg —
Subject CD123-CART Cell therapy 1e+06 cells/kg —
Subject CD123-CART Cell therapy 1e+07 cells/kg —
Subject CD133-CART Unknown 1e+06 cells/kg —
Subject CD133-CART Unknown 1e+07 cells/kg —
Subject CD33CART Cell therapy 1e+06 cells/kg —
Subject CD33CART Cell therapy 1e+07 cells/kg —
Subject CD34-CART Unknown 1e+06 cells/kg —
Subject CD34-CART Unknown 1e+07 cells/kg —
Subject CD38-CART Cell therapy 1e+06 cells/kg —
Subject CD38-CART Cell therapy 1e+07 cells/kg —
Subject CD56-CART Cell therapy 1e+06 cells/kg —
Subject CD56-CART Cell therapy 1e+07 cells/kg —
Subject Mucl-CART Unknown 1e+06 cells/kg —
Subject Mucl-CART Unknown 1e+07 cells/kg —

Indications

acute myeloid leukemia